Share on LinkedInShare on LinkedIn

ARTICLE · 12 FEBRUARY 2020

ECJ Rules For The First Time On "Pay-For-Delay" Agreements

On 30 January 2020 the European Court of Justice ("ECJ") clarified for the first time the criteria governing whether so-called "pay-for-delay" agreements entered into between originator and generic

European UnionAntitrust/Competition Law

On 30 January 2020 the European Court of Justice ("ECJ") clarified for the first time the criteria governing whether so-called "pay-for-delay" agreements entered into between originator and generic pharmaceutical companies fall foul of EU competition law rules. Such agreements are a form of patent dispute settlement, whereby in return for a value transfer, a generic manufacturer acknowledges the patent of the originator pharmaceutical company, and agrees to refrain from marketing its generic version of the drug in question for a specified period of time. Pay-for-delay agreements have been in the spotlight of the European Commission ("EC") and national competition authorities for over a decade.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from